About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
CF101
CF102
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Investor Information
Overview
News / Events
Press Releases
In The News
Research
Events Calendar
Presentations
Email Alerts
Company Information
Profile
Management
IR Contacts
FAQ
Financial Information
Quarterly & Annual Reports
Stock Information
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Section 16 Filings
Corporate Governance
Board of Directors
Governance Docs
Shareholders Meetings
Email Alerts
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Mar 27, 2015 4:29 PM EDT
Can-Fite Files 2014 Annual Report on Form 20-F
Mar 23, 2015 7:00 AM EDT
Can-Fite Signs Multi-Million Dollar Distribution Agreement for CF101 in Canada with Cipher Pharmaceuticals
Mar 18, 2015 7:00 AM EDT
Can-Fite Completes Development of Commercial Biomarker Test to Predict Patients' Response to Company Drugs
Feb 17, 2015 7:00 AM EST
Can-Fite Receives Notice of Allowance in U.S. for Psoriasis Patent
Feb 4, 2015 7:00 AM EST
Can-Fite Completes Phase II/III Trial for CF101 in Treatment of Psoriasis
Jan 27, 2015 7:00 AM EST
Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies
Jan 6, 2015 7:15 AM EST
Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications
Dec 30, 2014 7:00 AM EST
Can-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101
Dec 22, 2014 7:00 AM EST
Can-Fite Doses First Patient in Global Phase II Liver Cancer Trial for CF102
Dec 15, 2014 7:02 AM EST
Second Part of the Glaucoma Phase II study has been Approved in a European Country
<< Previous
1...
18
19
20
21
22
23
24
25
26
27
...30
Next >>
Show All